95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with lisocabtagene maraleucel (liso-cel) achieved a response, with 62.1% achieving complete response and 88.6% ...

Please provide your email address to receive an email when new articles are posted on . The results were presented at Society of Hematologic Oncology’s Annual Meeting. “We currently are really missing ...

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda This retrospective cohort study included patients ...

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from his presentation on extranodal marginal zone ...

BEIJING, Sept. 07, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA ...

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia. This is an ASCO Meeting Abstract from the 2012 ASCO ...

The National Institute for Health and Care Excellence (NICE) has approved the use of zanubrutinib (Brukinsa, BeiGene) on the NHS in England for the treatment of marginal zone lymphoma (MZL).

In the MZL cohort of TRANSCEND FL, Breyanzi delivered deep and durable responses in 95.5% of patients while demonstrating a consistent safety profile Breyanzi is now the only CAR T cell therapy ...

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® ...

Splenic marginal zone lymphoma (SMZL) is a rare, indolent B-cell lymphoma that principally involves the spleen, often extending to the bone marrow and peripheral blood, while nodal involvement remains ...

While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with ...